AfriAg Global
PLC
(To be renamed
Apollon Formularies PLC)
(“Company”)
12 April 2021
RESULT OF GENERAL
MEETING
AND
AQUIS REGULATORY
APPROVAL TO ACQUIRE APOLLON
The Company is pleased to announce that at the General Meeting
of the Company held today, all resolutions were duly passed. The
Company is also pleased to announce that AQSE Regulatory approval
to be admitted to the AQSE Growth Market has now been received to
acquire the entire issued share capital of Apollon Formularies
Limited, and it is expected that admission to trading will commence
tomorrow, 13 April 2021 at
8 a.m. The Enlarged Share Capital of
748,376,677 Ordinary Shares will be admitted to trading, comprising
31,710,011 Existing Ordinary Shares, 666,666,666 Consideration
Shares and 50,000,000 Placing Shares and Subscription Shares.
The Directors of the Company accept responsibility for the
contents of this announcement.
- Ends -
For additional information please contact:
AfriAg Global PLC
Stene
Jacobs
stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel:
+44 207 220 9795
Guy Miller
gm@peterhousecapital.com
Blytheweigh (Financial PR/IR-London)
Tel:
+44 207 138 3204
Tim Blythe
tim.blythe@blytheweigh.com
Megan
Ray
megan.ray@blytheweigh.com
